
Colin P Dinney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6687651/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell, 2014, 25, 152-165.	7.7	1,358
2	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
3	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	9.4	493
4	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2009, 15, 5060-5072.	3.2	386
5	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer and Metastasis Reviews, 2009, 28, 335-344.	2.7	324
6	STAGE SPECIFIC GUIDELINES FOR SURVEILLANCE AFTER RADICAL NEPHRECTOMY FOR LOCAL RENAL CELL CARCINOMA. Journal of Urology, 1998, 159, 1163-1167.	0.2	322
7	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nature Genetics, 2009, 41, 991-995.	9.4	321
8	Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VAC. Journal of Clinical Oncology, 2001, 19, 4005-4013.	0.8	284
9	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Reviews Urology, 2014, 11, 400-410.	1.9	267
10	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine, 2016, 12, 105-117.	2.7	257
11	Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology, 2006, 68, 549-553.	0.5	255
12	Micropapillary bladder cancer. Cancer, 2007, 110, 62-67.	2.0	253
13	Focus on bladder cancer. Cancer Cell, 2004, 6, 111-116.	7.7	252
14	Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle–Control Genes. American Journal of Human Genetics, 2006, 78, 464-479.	2.6	249
15	Surgical Management of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. Annals of Thoracic Surgery, 1997, 63, 1592-1600.	0.7	248
16	Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer. Cancer Research, 2008, 68, 2530-2537.	0.4	245
17	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2015, 67, 241-249.	0.9	235
18	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naÃ ⁻ ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. European Urology, 2016, 69, 855-862.	0.9	228

#	Article	IF	CITATIONS
19	EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCE. Journal of Urology, 2004, 172, 481-484.	0.2	225
20	The Efficacy and Complications of Salvage Cryotherapy of the Prostate. Journal of Urology, 1997, 157, 921-925.	0.2	211
21	The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 3-7.	0.8	211
22	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for highâ€risk upper tract transitional cell carcinoma. Cancer, 2010, 116, 3127-3134.	2.0	208
23	The Case for Early Cystectomy in the Treatment of Nonmuscle Invasive Micropapillary Bladder Carcinoma. Journal of Urology, 2006, 175, 881-885.	0.2	194
24	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020, 26, 1845-1851.	15.2	193
25	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 429-440.	0.8	188
26	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. Journal of Urology, 2010, 183, 2165-2170.	0.2	186
27	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU International, 2011, 107, 898-904.	1.3	184
28	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncology, The, 2021, 22, 107-117.	5.1	172
29	Expression Levels of Genes that Regulate Metastasis and Angiogenesis Correlate with Advanced Pathological Stage of Renal Cell Carcinoma. American Journal of Pathology, 2001, 158, 735-743.	1.9	170
30	Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. Journal of Clinical Oncology, 2008, 26, 121-126.	0.8	161
31	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. European Urology, 2010, 57, 300-309.	0.9	159
32	EVALUATION OF NMP22 IN THE DETECTION OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology, 1998, 159, 394-398.	0.2	157
33	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014, 120, 1794-1799.	2.0	154
34	Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Journal of Urology, 2014, 191, 40-47.	0.2	153
35	Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. Journal of Clinical Oncology, 2009, 27, 2592-2597.	0.8	148
36	Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. European Urology, 2013, 64, 307-313.	0.9	147

#	Article	IF	CITATIONS
37	Differences in Survival Among Patients With Sarcomatoid Carcinoma, Carcinosarcoma and Urothelial Carcinoma of the Bladder. Journal of Urology, 2007, 178, 2302-2307.	0.2	146
38	Isolation and Characterization of Metastatic Variants from Human Transitional Cell Carcinoma Passaged by Orthotopic Implantation in Athymic Nude Mice. Journal of Urology, 1995, 154, 1532-1538.	0.2	141
39	Origins of Bladder Cancer. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 149-174.	9.6	140
40	Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy. Journal of Clinical Oncology, 2003, 21, 2247-2253.	0.8	139
41	Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival. Journal of Clinical Oncology, 2005, 23, 5746-5756.	0.8	138
42	Plasmacytoid Urothelial Carcinoma, a Chemosensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. Journal of Urology, 2013, 189, 1656-1661.	0.2	138
43	ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology, 2013, 63, 36-44.	0.9	137
44	Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Molecular Genetics, 2014, 23, 1387-1398.	1.4	137
45	Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. European Urology, 2016, 69, 197-200.	0.9	136
46	Partial Cystectomy for Muscle Invasive Urothelial Carcinoma of the Bladder: A Contemporary Review of the M. D. Anderson Cancer Center Experience. Journal of Urology, 2006, 175, 2058-2062.	0.2	135
47	The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2010, 16, 4461-4467.	3.2	133
48	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU International, 2010, 105, 1402-1412.	1.3	132
49	Correlation between annual volume of cystectomy, professional staffing, and outcomes. Cancer, 2005, 104, 975-984.	2.0	130
50	Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology, 2017, 35, 3410-3416.	0.8	124
51	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. European Urology, 2016, 70, 611-620.	0.9	120
52	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU International, 2006, 98, 1176-1180.	1.3	116
53	Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1635-1642.	0.8	116
54	The p63 Protein Isoform ΔNp63α Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells. Journal of Biological Chemistry, 2013, 288, 3275-3288.	1.6	116

#	Article	IF	CITATIONS
55	Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clinical Cancer Research, 2003, 9, 3167-75.	3.2	116
56	Bortezomib Abolishes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells. Cancer Research, 2005, 65, 4902-4908.	0.4	108
5 7	Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. Urology, 2007, 70, 252-256.	0.5	107
58	Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial. Cancer and Metastasis Reviews, 2007, 26, 623-634.	2.7	107
59	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Reports, 2019, 27, 1781-1793.e4.	2.9	102
60	Chylous Ascites After Post-Chemotherapy Retroperitoneal Lymph Node Dissection: Review of the M. D. Anderson Experience. Journal of Urology, 2006, 176, 1463-1467.	0.2	101
61	Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2013, 190, 850-856.	0.2	101
62	Clinical Outcomes of cT1 Micropapillary Bladder Cancer. Journal of Urology, 2015, 193, 1129-1134.	0.2	101
63	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Human Molecular Genetics, 2011, 20, 4282-4289.	1.4	100
64	ls There a Therapeutic Role for Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Metastatic Transitional Cell Carcinoma of the Bladder?. Journal of Urology, 2003, 169, 2113-2117.	0.2	98
65	Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891.	3.2	98
66	Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ: British Medical Journal, 2018, 360, k134.	2.4	97
67	Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells. Clinical Cancer Research, 2008, 14, 1478-1486.	3.2	96
68	New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine. Clinical Cancer Research, 2011, 17, 2608-2612.	3.2	96
69	Evaluation of the Relevance of Lymph Node Density in a Contemporary Series of Patients Undergoing Radical Cystectomy. Journal of Urology, 2006, 176, 53-57.	0.2	94
70	The Risk of Upper Tract Recurrence Following Cystectomy in Patients with Transitional Cell Carcinoma Involving the Distal Ureter. Journal of Urology, 1996, 155, 501-503.	0.2	92
71	The stabilization and targeting of surfactant-synthesized gold nanorods. Nanotechnology, 2009, 20, 434005.	1.3	92
72	Upper urinary tract tumors with nontransitional histology: A single-center experience. Urology, 2006, 67, 518-523.	0.5	90

#	Article	IF	CITATIONS
73	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
74	The Relationship of Local Control to Distant Metastasis in Muscle Invasive Bladder Cancer. Journal of Urology, 1995, 154, 2059-2064.	0.2	89
75	Genetic Instability in Bladder Cancer Assessed by the Comet Assay. Journal of the National Cancer Institute, 2003, 95, 540-547.	3.0	89
76	Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer. Clinical Cancer Research, 2005, 11, 1408-1415.	3.2	88
77	Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy. Urology, 2010, 76, 1419-1424.	0.5	88
78	High-Order Interactions among Genetic Variants in DNA Base Excision Repair Pathway Genes and Smoking in Bladder Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 84-91.	1.1	87
79	Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 327-333.	0.8	86
80	Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. Journal of Urology, 2011, 185, 456-461.	0.2	86
81	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis, 2009, 30, 2047-2052.	1.3	85
82	Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder. Cancer, 2007, 110, 764-769.	2.0	84
83	Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. Journal of Urology, 2010, 183, 929-934.	0.2	84
84	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	1.6	83
85	Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. International Journal of Cancer, 2007, 120, 2208-2213.	2.3	82
86	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. Urology, 2014, 83, 863-868.	0.5	82
87	Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer. Journal of Urology, 2008, 179, 353-358.	0.2	80
88	Plasma microRNA profiles for bladder cancer detection. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1701-1708.	0.8	80
89	Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer. Molecular Cancer Therapeutics, 2013, 12, 1245-1254.	1.9	79
90	Correlation of Metastasis Related Gene Expression and Relapse-Free Survival in Patients With Locally Advanced Bladder Cancer Treated With Cystectomy and Chemotherapy. Journal of Urology, 2004, 171, 570-574.	0.2	78

#	Article	IF	CITATIONS
91	Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial. Journal of Urology, 2012, 187, 862-867.	0.2	78
92	Urachal carcinoma: a pathologic and clinical study of 46 cases. Human Pathology, 2015, 46, 1808-1814.	1.1	78
93	Gefitinib Reverses TRAIL Resistance in Human Bladder Cancer Cell Lines via Inhibition of AKT-Mediated X-Linked Inhibitor of Apoptosis Protein Expression. Cancer Research, 2007, 67, 1430-1435.	0.4	77
94	Targeted therapies in bladder cancer—an update. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 433-438.	0.8	77
95	Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein. Molecular Therapy, 2004, 10, 525-532.	3.7	76
96	Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair, 2008, 7, 141-148.	1.3	76
97	Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells. Cancer Research, 2005, 65, 10524-10535.	0.4	75
98	Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bladder Cancer, 2015, 1, 29-30.	0.2	75
99	Telomere Dysfunction in Peripheral Lymphocytes as a Potential Predisposition Factor for Renal Cancer. Journal of Urology, 2007, 178, 1492-1496.	0.2	74
100	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer. Cancer, 2013, 119, 540-547.	2.0	74
101	A Genome-Wide Association Study Identifies a Locus on Chromosome 14q21 as a Predictor of Leukocyte Telomere Length and as a Marker of Susceptibility for Bladder Cancer. Cancer Prevention Research, 2011, 4, 514-521.	0.7	73
102	Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells. Cancer Research, 2004, 64, 8973-8979.	0.4	72
103	Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clinical Cancer Research, 2002, 8, 1258-70.	3.2	72
104	Matrix Metalloproteinase Polymorphisms and Bladder Cancer Risk. Cancer Research, 2006, 66, 11644-11648.	0.4	71
105	Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Laboratory Investigation, 2008, 88, 694-721.	1.7	71
106	p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. PLoS ONE, 2012, 7, e30206.	1.1	71
107	Risk of Urethral, Vaginal and Cervical Involvement in Patients Undergoing Radical Cystectomy for Bladder Cancer: Results of a Contemporary Cystectomy Series from M. D. Anderson Cancer Center. Journal of Urology, 1997, 157, 2120-2123.	0.2	70
108	Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer. Journal of Clinical Oncology, 2006, 24, 5528-5535.	0.8	70

#	Article	IF	CITATIONS
109	Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection. Journal of the National Cancer Institute, 2008, 100, 1401-1411.	3.0	68
110	Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting. PLoS ONE, 2013, 8, e57284.	1.1	68
111	Projecting Individualized Probabilities of Developing Bladder Cancer in White Individuals. Journal of Clinical Oncology, 2007, 25, 4974-4981.	0.8	67
112	Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop. Urology, 2014, 83, 262-265.	0.5	67
113	Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Therapy, 2002, 9, 687-691.	2.2	66
114	Phase 1 prospective evaluation of the oncological adequacy of robotic assisted videoâ€endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU International, 2013, 111, 1068-1074.	1.3	66
115	Matrix Metalloproteinase Polymorphisms Are Associated with Bladder Cancer Invasiveness. Clinical Cancer Research, 2007, 13, 2614-2620.	3.2	64
116	High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis, 2007, 28, 2160-2165.	1.3	64
117	Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 38-45.	0.8	64
118	Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. Journal of Urology, 2010, 184, 888-894.	0.2	64
119	Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU International, 2011, 108, 1119-1123.	1.3	64
120	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU International, 2007, 100, 1377-1384.	1.3	63
121	Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2008, 14, 224-229.	3.2	63
122	Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. Urology, 2009, 73, 147-152.	0.5	63
123	The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics, 2004, 3, 279-90.	1.9	63
124	PO Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology, 2007, 52, 769-776.	0.9	61
125	The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clinical Cancer Research, 2002, 8, 1863-70.	3.2	61
126	Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology, 2003, 61, 1151-1155.	0.5	60

#	Article	IF	CITATIONS
127	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Molecular Cancer Therapeutics, 2007, 6, 277-285.	1.9	60
128	Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy. Clinical Cancer Research, 2006, 12, 4671-4677.	3.2	59
129	Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells. Cancer Biology and Therapy, 2007, 6, 872-879.	1.5	59
130	Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients. Journal of Urology, 2010, 183, 87-93.	0.2	58
131	Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 377-394.	0.9	57
132	Bladder Cancer: Narrowing the Gap Between Evidence and Practice. Journal of Clinical Oncology, 2009, 27, 5680-5684.	0.8	56
133	Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection. Journal of Urology, 2011, 185, 79-84.	0.2	55
134	New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. European Urology, 2014, 66, 609-610.	0.9	55
135	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis, 2010, 31, 1387-1391.	1.3	53
136	Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts. Cancer Research, 2004, 64, 4601-4610.	0.4	52
137	Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 2008, 112, 2467-2474.	2.0	52
138	Self-assembled fluorescent magnetic nanoprobes for multimode-biomedical imaging. Biomaterials, 2010, 31, 9310-9319.	5.7	52
139	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Pathology, 2017, 147, 500-506.	0.4	52
140	Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. , 1999, 86, 2212-2216.		51
141	Differential expression of GATA-3 in urothelial carcinoma variants. Human Pathology, 2014, 45, 1466-1472.	1.1	51
142	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e1-59.e8.	0.8	51
143	Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. European Urology Focus, 2017, 3, 258-264.	1.6	51
144	RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology, 1998, 160, 1285-1290.	0.2	50

#	Article	IF	CITATIONS
145	Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition. Clinical Cancer Research, 2008, 14, 2236-2244.	3.2	49
146	Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer, 2010, 116, 340-346.	2.0	49
147	Significance of Upper Urinary Tract Urothelial Thickening and Filling Defect Seen on MDCT Urography in Patients With a History of Urothelial Neoplasms. American Journal of Roentgenology, 2010, 195, 959-965.	1.0	49
148	Growth factors and receptors as prognostic markers in urothelial carcinoma. Current Urology Reports, 2008, 9, 55-61.	1.0	48
149	Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Human Pathology, 2009, 40, 1448-1452.	1.1	48
150	Micropapillary bladder cancer: Current treatment patterns and review of the literature. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 826-832.	0.8	48
151	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Human Pathology, 2018, 79, 57-65.	1.1	48
152	Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology, 1997, 50, 673-677.	0.5	47
153	Clinical Model of Cost of Bladder Cancer in the Elderly. Urology, 2008, 71, 519-525.	0.5	47
154	Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagnostic Cytopathology, 1999, 20, 285-290.	0.5	46
155	Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Laboratory Investigation, 2005, 85, 532-549.	1.7	46
156	Genome-Wide Association Study Identifies Variants in Casein Kinase II (<i>CSNK2A2</i>) to be Associated With Leukocyte Telomere Length in a Punjabi Sikh Diabetic Cohort. Circulation: Cardiovascular Genetics, 2014, 7, 287-295.	5.1	46
157	Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non–Muscle-Invasive Bladder Cancer. Cancer Prevention Research, 2010, 3, 1235-1245.	0.7	45
158	Dietary Intake of Vegetables and Fruits and the Modification Effects of <i>GSTM1</i> and <i>NAT2</i> Genotypes on Bladder Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2090-2097.	1.1	44
159	Upper tract urothelial carcinoma: Impact of time to surgery. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 266-272.	0.8	44
160	Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy. Urology, 2011, 78, 61-67.	0.5	43
161	Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. Journal of Urology, 2008, 180, 164-167.	0.2	42
162	Organ Preservation for Muscle-Invasive Bladder Cancer by Transurethral Resection. Urology, 2007, 70, 473-476.	0.5	41

#	Article	IF	CITATIONS
163	Uroplakin II Is a More Sensitive Immunohistochemical Marker Than Uroplakin III in Urothelial Carcinoma and Its Variants. American Journal of Clinical Pathology, 2014, 142, 864-871.	0.4	41
164	Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Scientific Reports, 2017, 7, 40714.	1.6	41
165	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget, 2016, 7, 80164-80174.	0.8	40
166	Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clinical Epigenetics, 2018, 10, 71.	1.8	39
167	Vitamins C and K3 Sensitize Human Urothelial Tumors to Gemcitabine. Journal of Urology, 2006, 176, 1642-1647.	0.2	38
168	Personal Permanent Hair Dye Use Is Not Associated with Bladder Cancer Risk: Evidence from a Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1746-1749.	1.1	38
169	Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis, 2006, 28, 698-703.	1.3	38
170	Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis, 2013, 34, 1006-1011.	1.3	38
171	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	1.4	38
172	Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 456-462.	0.8	36
173	Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer. Cancer Prevention Research, 2010, 3, 505-517.	0.7	36
174	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International, 2017, 119, 684-691.	1.3	36
175	A multiplexed, particleâ€based flow cytometric assay identified plasma matrix metalloproteinaseâ€7 to be associated with cancerâ€related death among patients with bladder cancer. Cancer, 2010, 116, 4513-4519.	2.0	35
176	Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU International, 2010, 106, 1799-1804.	1.3	35
177	Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells. PLoS ONE, 2013, 8, e69509.	1.1	35
178	Genetic subtypes of invasive bladder cancer. Current Opinion in Urology, 2015, 25, 449-458.	0.9	35
179	Novel fluorescence <i>inÂsitu</i> hybridizationâ€based definition of bacille Calmetteâ€Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU International, 2016, 117, 754-760.	1.3	35
180	Bladder cancer risk as modified by family history and smoking. Cancer, 2006, 107, 705-711.	2.0	34

#	Article	IF	CITATIONS
181	Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guérin. PLoS ONE, 2012, 7, e38533.	1.1	34
182	Therapy of invasive bladder cancer. Urology, 2006, 67, 56-59.	0.5	33
183	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World Journal of Urology, 2012, 30, 753-759.	1.2	33
184	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 821-824.	0.8	33
185	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. Journal of Endourology, 2017, 31, 946-953.	1.1	33
186	Complications of radical cystectomy: Impact of the timing of perioperative chemotherapy. Urology, 1996, 47, 826-830.	0.5	32
187	Schedule Dependent Efficacy of Gefitinib and Docetaxel for Bladder Cancer. Journal of Urology, 2006, 176, 787-792.	0.2	32
188	Combination therapy with IFN-α plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Molecular Cancer Therapeutics, 2006, 5, 3032-3041.	1.9	32
189	Plasma vitamins E and A and risk of bladder cancer: a case–control analysis. Cancer Causes and Control, 2008, 19, 981-992.	0.8	32
190	Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy. Journal of Urology, 2011, 185, 1216-1221.	0.2	32
191	Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. British Journal of Cancer, 2013, 108, 2372-2380.	2.9	32
192	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 480-486.	0.8	32
193	Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. Journal of Urology, 2015, 194, 1771-1776.	0.2	32
194	The Vascular-Targeting Fusion Toxin VEGF121/rGel Inhibits the Growth of Orthotopic Human Bladder Carcinoma Tumors. Neoplasia, 2005, 7, 912-920.	2.3	31
195	Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette–Guerin Instillation for Non-muscle Invasive Bladder Cancer. Annals of Surgical Oncology, 2015, 22, 4104-4110.	0.7	31
196	Intrinsic subtypes and bladder cancer metastasis. Asian Journal of Urology, 2016, 3, 260-267.	0.5	31
197	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	1.2	31
198	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports, 2019, 26, 2241-2256.e4.	2.9	31

#	Article	IF	CITATIONS
199	Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. European Urology, 2019, 75, 8-10.	0.9	31
200	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-GuA©rin: Implications for Clinical Trial Design. Journal of Urology, 2021, 205, 1612-1621.	0.2	31
201	Neoadjuvant chemotherapy for bladder cancer. World Journal of Urology, 2006, 24, 531-542.	1.2	30
202	Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa. Journal of Urology, 2013, 190, 1404-1409.	0.2	30
203	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
204	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 3.e17-3.e27.	0.8	29
205	Genetic polymorphism in bladder cancer. Frontiers in Bioscience - Landmark, 2007, 12, 192.	3.0	29
206	Prognostic risk stratification of pathological stage T2NO bladder cancer after radical cystectomy. BJU International, 2011, 108, 687-692.	1.3	28
207	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU International, 2018, 122, 89-98.	1.3	28
208	Risk factors for falls in older patients with cancer. BMJ Supportive and Palliative Care, 2018, 8, 34-37.	0.8	28
209	Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urologic Clinics of North America, 2003, 30, 791-802.	0.8	27
210	Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?. Current Opinion in Urology, 2006, 16, 344-349.	0.9	26
211	Receptor Heterodimerization: A New Mechanism for Platelet-Derived Growth Factor Induced Resistance to Anti-Epidermal Growth Factor Receptor Therapy for Bladder Cancer. Journal of Urology, 2011, 185, 693-700.	0.2	26
212	Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 1325-1338.	1.5	26
213	Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. International Journal of Cancer, 2012, 131, 1892-1903.	2.3	26
214	Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surgical Innovation, 2018, 25, 242-250.	0.4	26
215	Management of urethral recurrence after orthotopic urinary diversion. BJU International, 2010, 106, 56-61.	1.3	25
216	Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. European Urology, 2016, 70, 778-785.	0.9	25

#	Article	IF	CITATIONS
217	Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. European Urology Focus, 2020, 6, 88-94.	1.6	25
218	Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncology Reports, 2001, 8, 955-64.	1.2	25
219	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1108-1115.	0.8	24
220	Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. European Urology Oncology, 2022, 5, 84-91.	2.6	24
221	Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: Is there a benefit to either approach?. Urology, 2006, 67, 466-471.	0.5	23
222	Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy. Urology, 2014, 84, 1147-1151.	0.5	23
223	Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic TO Stage in Bladder Cancer Treated with Radical Cystectomy. European Urology Focus, 2018, 4, 720-724.	1.6	23
224	Dietary patterns and risk of recurrence and progression in nonâ€muscleâ€invasive bladder cancer. International Journal of Cancer, 2018, 142, 1797-1804.	2.3	23
225	Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Canadian Urological Association Journal, 2018, 13, 24-28.	0.3	23
226	Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Annals of Surgical Oncology, 2016, 23, 4110-4114.	0.7	22
227	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery, 2017, 161, 1246-1254.	1.0	22
228	Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer, 2006, 107, 1491-1495.	2.0	21
229	Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU International, 2012, 110, E590-5.	1.3	21
230	The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World Journal of Urology, 2019, 37, 2041-2049.	1.2	21
231	Genetic Variations in the Transforming Growth Factor Beta Pathway as Predictors of Bladder Cancer Risk. PLoS ONE, 2012, 7, e51758.	1.1	20
232	Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery. Urologia Internationalis, 2011, 87, 42-48.	0.6	19
233	Is folic acid safe for non–muscle-invasive bladder cancer patients? An evidence-based cohort study. American Journal of Clinical Nutrition, 2018, 107, 208-216.	2.2	19
234	Overall survival in older patients with cancer. BMJ Supportive and Palliative Care, 2020, 10, 25-35.	0.8	19

#	Article	IF	CITATIONS
235	Adenoviral Mediated Interferon-α 2b Gene Therapy Suppresses the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Superficial Bladder Cancer. Journal of Urology, 2007, 177, 1900-1906.	0.2	18
236	p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 477-486.	1.5	18
237	Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prevention Research, 2015, 8, 607-613.	0.7	18
238	High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis. Oncolmmunology, 2017, 6, e1265719.	2.1	18
239	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	1.9	18
240	Genetic Variants in Telomere-Maintenance Genes and Bladder Cancer Risk. PLoS ONE, 2012, 7, e30665.	1.1	18
241	Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Research, 2003, 63, 4017-20.	0.4	17
242	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Current Opinion in Urology, 2004, 14, 295-300.	0.9	16
243	Clinical significance of ureteric â€~skip lesions' at the time of radical cystectomy: the <scp>M</scp> . <scp>D</scp> . <scp>A</scp> nderson experience and literature review. BJU International, 2014, 113, E28-33.	1.3	16
244	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. Journal of Urology, 2001, 165, 1152-1157.	0.2	15
245	The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics, 2005, 6, 575-584.	0.6	15
246	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 639.e1-639.e9.	0.8	15
247	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2022, 207, 70-76.	0.2	15
248	INTERLEUKIN-8 (IL-8) EXPRESSION REGULATES TUMORIGENICITY AND METASTASIS IN HUMAN BLADDER CANCER. Journal of Urology, 1999, , 120.	0.2	15
249	Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer, 2007, 110, 282-288.	2.0	14
250	Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Supportive Care in Cancer, 2018, 26, 1561-1568.	1.0	14
251	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Journal of Urology, 2021, 206, 577-585.	0.2	14
252	Cardiac History and Risk of Post-cystectomy Cardiac Complications. Urology, 2009, 74, 1085-1089.	0.5	13

#	Article	IF	CITATIONS
253	EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY. Journal of Urology, 2009, 181, 629.	0.2	13
254	The role of radical cystectomy in patients with clinical T4b bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 157-161.	0.8	13
255	Comprehensive pathwayâ€based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer, 2012, 118, 205-215.	2.0	13
256	Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs in R and D, 2017, 17, 297-304.	1.1	13
257	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with nonâ€muscleâ€invasive bladder cancer treated with bacillus Calmette–Guérin. BJU International, 2021, 128, 65-71.	1.3	13
258	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget, 2017, 8, 34205-34222.	0.8	13
259	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Expert Review of Anticancer Therapy, 2007, 7, 1015-1026.	1.1	12
260	Benzo(<i>a</i>)pyrene Diol Epoxide-Induced Chromosome 9p21 Aberrations Are Associated with Increased Risk of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2445-2450.	1.1	12
261	Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. Journal of Sexual Medicine, 2020, 17, 1995-2004.	0.3	12
262	Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. Genes and Cancer, 2016, 7, 229-239.	0.6	12
263	The origin of bladder cancer from mucosal field effects. IScience, 2022, 25, 104551.	1.9	12
264	The use of urine-based biomarkers in bladder cancer. Urology, 2006, 67, 62-64.	0.5	11
265	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. Journal of Geriatric Oncology, 2018, 9, 81-83.	0.5	11
266	Salvage topical therapy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 2027-2034.	1.2	11
267	Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer. Oncotarget, 2018, 9, 14895-14908.	0.8	11
268	Clinical Applications for Targeted Therapy in Bladder Cancer. Urologic Clinics of North America, 2005, 32, 239-246.	0.8	10
269	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. European Urology Focus, 2017, 3, 577-583.	1.6	10
270	Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncolmmunology, 2019, 8, e1577125.	2.1	10

#	Article	IF	CITATIONS
271	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World Journal of Urology, 2019, 37, 2691-2698.	1.2	10
272	Intravesical Gene Therapy. Urologic Clinics of North America, 2020, 47, 93-101.	0.8	10
273	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU International, 2021, 127, 528-537.	1.3	10
274	Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. Molecular Therapy - Methods and Clinical Development, 2021, 22, 360-376.	1.8	10
275	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Journal of Urology, 2020, 203, 283-291.	0.2	10
276	Concepts for banking tissue in urologic oncology–the International Bladder Cancer Bank. Clinical Cancer Research, 2005, 11, 413-5.	3.2	10
277	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Journal of Urology, 2021, 206, 548-557.	0.2	9
278	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0,	0.4	9
279	If cystectomy is insufficient, what is an urologist to do?. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 475-478.	0.8	8
280	Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2009, 9, 807-813.	1.1	8
281	Detection of Bladder Cancer Using Proteomic Profiling of Urine Sediments. PLoS ONE, 2012, 7, e42452.	1.1	8
282	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 469-476.	0.8	8
283	Dose dense MVAC prior to radical cystectomy: a real-world experience. World Journal of Urology, 2017, 35, 1729-1736.	1.2	8
284	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer, 2017, 3, 145-146.	0.2	8
285	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncology, 2019, 5, 1790.	3.4	8
286	Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. European Urology Oncology, 2019, 2, 286-293.	2.6	8
287	What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology, 2021, 157, 181-187.	0.5	8
288	Reducedâ€dose bacillus Calmetteâ€Guérin (BCG) in an era of BCG shortage: realâ€world experience from a tertiary cancer centre. BJU International, 2022, 130, 323-330.	1.3	8

#	Article	IF	CITATIONS
289	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European Urology, 2022, 81, 223-228.	0.9	8
290	Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. Journal of Clinical Ultrasound, 1995, 23, 263-265.	0.4	7
291	Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs, 2007, 12, 435-448.	1.0	7
292	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 301.e17-301.e28.	0.8	7
293	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Journal of Urology, 2021, 206, 1258-1267.	0.2	7
294	Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. Journal of Urology, 2022, 207, 551-558.	0.2	7
295	All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. Journal of Urology, 2022, 208, 284-291.	0.2	7
296	Original Articles: Bladder Cancer: Management of Transitional Cell Carcinoma Involving Von Brunn's Nests. Journal of Urology, 1995, 153, 944-949.	0.2	6
297	Office Cystoscopy and Transrectal Ultrasound-guided Prostate Biopsies Pose Minimal Risk: Prospective Evaluation of 921 Procedures. Urology, 2009, 73, 1175-1178.	0.5	6
298	Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. Journal of Endourology, 2018, 32, 806-811.	1.1	6
299	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e1-237.e5.	0.8	6
300	1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. Journal of Urology, 2007, 177, 502-502.	0.2	6
301	Gene therapy for superficial bladder cancer. Expert Review of Anticancer Therapy, 2001, 1, 531-540.	1.1	5
302	Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?. Journal of Urology, 2008, 180, 1146-1153.	0.2	5
303	Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy. Journal of Urology, 2016, 195, 1646-1647.	0.2	5
304	Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. European Urology Focus, 2019, 5, 664-675.	1.6	5
305	Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response. BJU International, 2021, 128, 634-641.	1.3	5
306	Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World Journal of Urology, 2021, 39, 4143-4149.	1.2	5

#	Article	IF	CITATIONS
307	Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 176-182.	0.9	5
308	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 354.e19-354.e26.	0.8	4
309	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Molecular Cancer Research, 2020, 18, 811-821.	1.5	4
310	Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer, 2021, 7, 243-252.	0.2	4
311	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 4345-4354.	1.2	4
312	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology, 2015, 4, 273-82.	0.6	4
313	Uncommon Cancers of the Bladder. , 2006, , 18-26.		3
314	A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nature Reviews Urology, 2006, 3, 472-473.	1.4	3
315	Delayed Ureterectomy after Incomplete Nephroureterectomy for Upper Tract Urothelial Carcinoma: Pathologic Findings and Outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 817-822.	0.7	3
316	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609–10. European Urology, 2015, 67, e76-e78.	0.9	3
317	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World Journal of Urology, 2016, 34, 695-701.	1.2	3
318	Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. Asian Journal of Urology, 2017, 4, 124-127.	0.5	3
319	Effects of thiazolidinedione in patients with active bladder cancer. BJU International, 2018, 121, 244-251.	1.3	3
320	Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 247-254.	0.8	3
321	Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. American Journal of Clinical Pathology, 2020, 154, 208-214.	0.4	3
322	Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. Oncotarget, 2017, 8, 88782-88791.	0.8	3
323	Multimodal kidneyâ€preserving approach in localised and locally advanced highâ€risk upper tract urothelial carcinoma. BJUI Compass, 2022, 3, 37-44.	0.7	3
324	Lentiviral interferon: A novel method for gene therapy in bladder cancer. Molecular Therapy - Oncolytics, 2022, 26, 141-157.	2.0	3

#	Article	IF	CITATIONS
325	The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition. Cancer Prevention Research, 2009, 2, 1001-1002.	0.7	2
326	High Risk Populations and Cystectomy Outcomes. Journal of Urology, 2009, 182, 10-11.	0.2	2
327	The International Bladder Cancer Network. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 375-376.	0.8	2
328	Intelligent Clinical Decision Support Systems for Non-invasive Bladder Cancer Diagnosis. Lecture Notes in Computer Science, 2011, , 253-262.	1.0	2
329	Reply by the Authors. Urology, 2014, 84, 495-496.	0.5	2
330	High-grade neuroendocrine carcinoma of the urachus—report of 3 cases. Human Pathology, 2017, 67, 126-133.	1.1	2
331	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer, 2017, 3, 147-148.	0.2	2
332	Should chemotherapy still be used to treat all muscle invasive bladder cancer in the "era of immunotherapy�. Expert Review of Anticancer Therapy, 2019, 19, 543-545.	1.1	2
333	Bacillus Calmette-Guérin Salvage Therapy. Urologic Clinics of North America, 2020, 47, 1-4.	0.8	2
334	Impact of upper tract urothelial carcinoma on response to BCG in patients with nonâ€muscleâ€invasive bladder cancer. BJU International, 2021, 128, 568-574.	1.3	2
335	1240: Prospective Evidence Supporting the Utility of Neooadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center. Journal of Urology, 2006, 175, 399-399.	0.2	2
336	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. Bladder Cancer, 2022, 8, 113-117.	0.2	2
337	Re: D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer. European Urology, 2009, 56, 745-746.	0.9	1
338	Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget, 2015, 6, 4097-4109.	0.8	1
339	Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer. Medicine (United States), 2016, 95, e4500.	0.4	1
340	Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. European Urology, 2019, 75, 1034-1035.	0.9	1
341	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5. European Urology, 2020, 77, 436-438.	0.9	1
342	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. European Urology, 2021, 79, 428-429.	0.9	1

#	Article	IF	CITATIONS
343	Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. European Urology Oncology, 2021, , .	2.6	1
344	Oncologic Equipoise Between Robotic and Open Radical Cystectomy. Journal of Endourology, 2021, 35, 1168-1176.	1.1	1
345	1647: Differences in Survival Between Patients with Sarcomatoid Carcinoma, Carcinosarcoma and Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2007, 177, 546-546.	0.2	1
346	Should Patients With Nonâ€Muscleâ€Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?. BJU International, 2021, , .	1.3	1
347	How I do it: Radical cystectomy: Posterior dissection following prior therapy. , 1997, 64, 165-166.		0
348	Bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 479-480.	0.8	0
349	Preface. Cancer and Metastasis Reviews, 2009, 28, 267-267.	2.7	0
350	Accuracy of Computed Tomography for Identifying Locally Advanced Disease in Patients with Muscle-Invasive Bladder Cancer. UroToday International Journal, 2013, 06, .	0.1	0
351	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. Molecular Pathology Library, 2018, , 85-101.	0.1	Ο
352	Reply by Authors. Journal of Urology, 2021, 205, 1620-1621.	0.2	0
353	Reply by Authors. Journal of Urology, 2021, 206, 1267.	0.2	Ο
354	Small Cell Urothelial Carcinoma. , 2012, , 173-181.		0
355	Whole-organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. SSRN Electronic Journal, 0, , .	0.4	Ο